PharVision Advisers’s Pearson PSO Stock Holding History

PharVision Advisers’s Portfolio PSO Stock Details PSO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-16,583	Closed	-$235K	–	943
2025 Q3	$235K	Buy	+16,583	New	+$239K	0.13%	377

Other funds holding PSO

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

Optiver Holding Amsterdam, Netherlands $371B AUM 64.6% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

PharVision Advisers's PSO Position: Q4 2025 in Review

PharVision Advisers sold out of Pearson (PSO) in Q4 2025, closing a stake of 16,583 shares — an estimated $235K sold.

PharVision Advisers first reported a position in PSO in Q3 2025 and held it in 1 quarter. The position peaked at $235K in Q3 2025. 193 funds tracked by Wall St. Rank hold PSO as of Q4 2025.

PharVision Advisers reported no remaining Pearson position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 16,583 Pearson shares in Q4 2025, an estimated $235K.
PharVision Advisers first reported a position in Pearson in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Pearson position peaked at $235K in Q3 2025.
193 funds tracked by Wall St. Rank held Pearson as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.